E 'match the phase II for a new topical medication that would act at the same time inhibiting the dipeptidyl peptidase IV and aminopeptidase N.
The drug, whose acronym is provisional IP10: C8, deriva da un brevetto della tedesca Immune Technologies and Medicine ( IMTM ) chiamato Peptidase Targeted Immune Regulation (PETIR™)
PETIR™ therapy involves the combined inhibition of two peptidases that are chiefly responsible for immune response (DPIV and APN families), by using dual inhibitors. PETIR™ is realized by the use of single NCEs that combine both inhibitory modes of action into a single substance.
This completely new approach acts both, on central regulatory mechanisms of the immune system, by activation of regulatory T cells and direct inhibition of activation and proliferation of activated immune effector cells. This holds true for TH1 as well as TH2 mediated immune responses.
0 comments:
Post a Comment